A 16q deletion involving FOXF1 enhancer is associated to pulmonary capillary hemangiomatosis. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Dello Russo, Patrizia; Franzoni, Alessandra; Baldan, Federica; Puppin, Cinzia; De Maglio, Giovanna; Pittini, Carla; Cattarossi, Luigi; Pizzolitto, Stefano; Damante, Giuseppe
• Is Part Of: BMC medical genetics. Volume 16:Issue 1(2015)
• Page Start: 1
• Page End: 6
• Publication Date: 2015-12
• Subjects: Pulmonary capillary hemangiomatosis -- Chromosomal abnormalities -- Deletion -- Gene regulation; Medical genetics -- Periodicals; 616.04205
• DOI: 10.1186/s12881-015-0241-7
• Languages: English
• ISSNs: 1471-2350

Abstract

Abstract Background Pulmonary capillary hemangiomatosis (PCH) is an uncommon pulmonary disorder, with variable clinical features depending on which lung structure is affected, and it is usually linked to pulmonary arterial hypertension. Congenital PCH has been very rarely described and, so far, the only causative gene identified isEIF2AK4, which encodes for a translation initiation factor. However, not all PCH cases might carry a mutation in this gene. Case presentation We report the clinical and cytogenetic characterization of a patient (male, newborn, first child of healthy non-consanguineous parents) died after three days of life with severe neonatal pulmonary hypertension, due to diffuse capillary hemangiomatosis diagnosed post mortem. Conventional karyotyping, Microarray-Based Comparative Genomic Hydridization (CGHa) and quantitative PCR were performed. CGHa revealed a heterozygous chromosome 16q23.3q24.1 interstitial deletion, spanning about 2.6 Mb and involving aFOXF1 gene enhancer. Quantitative PCR showed that the proband's deletion wasde novo . Microsatellite analysis demonstrate that the deletion occurred in the maternal chromosome 16. Conclusion FOXF1 loss of function mutation have been so far identified in alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), a lung disease different from PCH. Our data suggest the hypothesis that disruption of theFOXF1 gene enhancer could be a genetic determinant of PCH. Moreover, our findings support the idea thatFOXF1 is a paternally imprinted gene.